Comparison: antimuscarinic vs placebo

OutcomeMeta- analysis detailsSummary Statisticsp (hetero) and I2Comments:Study qualityDirectnessImprecisionInconsistencyReporting BiasGRADE CommentsGRADE Evidence Rating
Global improvement of IBS symptoms (no. patients)4 trials; 483 patients; from meta analysis; (parallel design);RR=1.38 (95%CI 1.22, 1.57)p=0.08; I2 =57%statistically significant, favours antimuscarinic agentGoodIndirect Setting - minor, secondary care OPDPreciseminor inconsistency---Antimuscarinic agents subgroup. 1/4 had missing data. Sensitive to random effects/fixed effects modelLow

From: Appendix F, Grading the evidence

Cover of Irritable Bowel Syndrome in Adults
Irritable Bowel Syndrome in Adults: Diagnosis and Management of Irritable Bowel Syndrome in Primary Care [Internet].
NICE Clinical Guidelines, No. 61.
National Collaborating Centre for Nursing and Supportive Care (UK).
Copyright © 2008, Royal College of Nursing.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.